Gene therapy products present a unique set of challenges for the control of host cell protein impurities.
Andrew Hanneman
Advertisement
Andrew Hanneman, PhD, is scientific advisor, biologics testing with Charles River.
Articles by Andrew Hanneman
Advertisement
Latest Updated Articles
Detecting Residual HCPs Demands a Holistic ApproachPublished: July 15th 2021 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Data Quality, Not Regulation, Is the True Barrier to AI in Biologics
2
RNAnalytics CPHI Interview, Part Two: Nanoparticle Case Studies and Response to US mRNA Pullback
3
Strategic Shifts for Speed, Resilience, and Long-Term Sustainability in Biomanufacturing
4
How Is AI Transforming Biomanufacturing and Biopharma Workforce Training?
5
